Add like
Add dislike
Add to saved papers

Plasmon-assisted degradation of methylene blue with Ag/AgCl/montmorillonite nanocomposite under visible light.

Metal-semiconductor compounds, such as Ag/AgX (X=Cl, Br, I), enable visible light absorption and separation of photogenerated electron-hole through surface plasmon resonance (SPR) effect. However, the electron-hole generated and separated by light are vulnerable in Ag/AgX phase because of the occurrence of secondary recombined. In order to more effectively utilize the SPR photocatalytic effect, nanoparticles are located in a matrix. In this article, Ag/AgCl nanoparticles were synthesized in montmorillonite (MMT) matrix using dispersion method and light irradiation. The structure, composition and optical properties of such material were investigated by transmission electron microscopy (TEM), UV-visible diffuse reflectance spectroscopy (UV-Vis DRS), X-ray diffraction (XRD) and FTIR. Powder X-ray diffraction showed intercalation of Ag/AgCl nanoparticles into the clay layers. The as-prepared plasmonic photocatalyst exhibited an enhanced and stable photoactivity for the degradation of methylene blue (MB) under visible light. The high activity was attributed to the surface plasmon resonance (SPR) exhibited by Ag nanoparticles on the surface of AgCl. The detection of reactive species by radical scavengers displays that O2- and OH- are the main reactive species for the degradation of MB under visible light irradiation. The studies showed that 20 min illumination under visible light can complete degradation of methylene blue (MB), and indicate a high stability of photocatalytic degradation. The mechanism of separation of the photo-generated electrons and holes at the Ag/AgCl-MMT nanocomposite was discussed.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app